MedTrace Logo

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

NCT06175000 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-06-05

No results posted yet for this study

Summary

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

Conditions

Interventions

PROCEDURE

Cognitive Assessment

Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Quality of Life Assessment

Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.

Sponsors & Collaborators

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Prakash Ambady, MD · Providence Health & Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-13
Primary Completion
2028-09-15
Completion
2029-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06175000 on ClinicalTrials.gov